Navigation Links
CryoLife Announces Management Promotions
Date:8/4/2008

ATLANTA, Aug. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that Bruce G. Anderson has been promoted to vice president of U.S. sales and marketing, and that Richard C. Gridley has been promoted to vice president of international sales and marketing. Both men will report to Gerald B. Seery, senior vice president of worldwide sales and marketing. Additionally, the company has announced the promotion of Timothy M. Neja to vice president of laboratory operations. Mr. Neja will report to D. Ashley Lee, executive vice president, chief operating officer and chief financial officer.

In his new position, Mr. Anderson, 42, will be responsible for the U.S. direct sales force, U.S. marketing, and customer service. Mr. Anderson began his career at CryoLife in 1994 as a territory manager and has held increasingly important roles within the sales and marketing organization, most recently serving as senior director, U.S. sales and marketing. Prior to joining CryoLife, Mr. Anderson was with Dun and Bradstreet Business Credit Services.

Mr. Gridley, 37, will now manage sales and marketing in Canada, Asia- Pacific, and Central and South America. Mr. Gridley joined CryoLife in 2005 as marketing manager for BioGlue(R) Surgical Adhesive and most recently served as marketing manager, global bioadhesives. Previously, Mr. Gridley was with Global Link Logistics, Inc., Rusch Inc. and 3M Company.

Mr. Neja, 42, has most recently served as senior director of laboratory operations at CryoLife. In his new role, he will continue to be responsible for all laboratory operations, including tissue processing and BioGlue manufacturing, as well as purchasing and facilities management. Prior to joining CryoLife in 1997 as production manager, Mr. Neja was with Centeon.

"We are pleased to announce these well-deserved promotions within our management team," said Steven G. Anderson, CryoLife president and chief executive officer. "Bruce, Rich and Tim have each made substantial contributions to the success of the organization over the past several years, and we believe they will continue to enhance our ability to bring cutting-edge solutions to cardiac and vascular surgeons world-wide."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Chief Fleishman Hillard

Financial Officer and Phone: 404-739-0150

Chief Operating Officer

Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLifes Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007
2. CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results
3. CryoLifes BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery
4. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
5. Harvey Morgan Joins CryoLife Board of Directors
6. CryoLife Conducts Surgeons Cardiac Allograft Symposium
7. CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label
8. CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services
9. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
10. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
11. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... ... ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of ... as the new Vice President of Global Clinical Development. With more than 15 ... will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... science and biotechnology companies today announced it named Joan Siefert Rose as ... out of Durham, NC and will begin work immediately. , Rose most recently ...
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/27/2017)... 2017 A Europe-wide survey of institutes conducted ... animals in their research treat them with due care. The survey ... analysis of the results indicates that there is a strong commitment ... into practice the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the ...
Breaking Biology Technology:
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):